Literature DB >> 18378324

Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS.

Adi Vaknin-Dembinsky1, Steven D Brass, Steven Brass, Roopali Gandhi, Howard L Weiner.   

Abstract

IL-15 is a pro-inflammatory cytokine whose three-dimensional structure is similar to that of IL-2. IL-2 and IL-15 have similar as well as distinct biological functions. An active form of IL-15 that is membrane bound has also been described. Furthermore, IL-15 is known to play a role in autoimmune diseases. We thus investigated the expression of membrane bound IL-15 on monocytes (CD14+ cells) and studied its effect on T cell activation in MS patients. We found that unstimulated CD14+ cells from relapsing remitting MS patients had increased membrane bound IL-15. Those with high surface levels of IL-15 on monocytes were in the early stages of the disease. In addition, we found that T cells of MS patients had enhanced responsiveness to IL-15 and there was increased expression of IL-15 receptor on CD4+ T cells. Thus, IL-15 may be an important cytokine that drives Th1 responses early in the course of the disease and could serve as a target for immunotherapy and as an early marker in the immunologic staging of MS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378324      PMCID: PMC2747383          DOI: 10.1016/j.jneuroim.2008.01.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  33 in total

1.  IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection.

Authors:  X C Li; P Roy-Chaudhury; W W Hancock; R Manfro; M S Zand; Y Li; X X Zheng; P W Nickerson; J Steiger; T R Malek; T B Strom
Journal:  J Immunol       Date:  1998-07-15       Impact factor: 5.422

2.  Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand.

Authors:  K E Balashov; D R Smith; S J Khoury; D A Hafler; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology.

Authors:  H Ruchatz; B P Leung; X Q Wei; I B McInnes; F Y Liew
Journal:  J Immunol       Date:  1998-06-01       Impact factor: 5.422

4.  Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis.

Authors:  E W Thurkow; I M van der Heijden; F C Breedveld; T J Smeets; M R Daha; P M Kluin; A E Meinders; P P Tak
Journal:  J Pathol       Date:  1997-04       Impact factor: 7.996

Review 5.  The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.

Authors:  T A Waldmann; Y Tagaya
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

6.  IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS).

Authors:  P Kivisäkk; D Matusevicius; B He; M Söderström; S Fredrikson; H Link
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

7.  Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15.

Authors:  T Musso; L Calosso; M Zucca; M Millesimo; D Ravarino; M Giovarelli; F Malavasi; A N Ponzi; R Paus; S Bulfone-Paus
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

8.  Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis.

Authors:  C Agostini; L Trentin; M Facco; R Sancetta; A Cerutti; C Tassinari; L Cimarosto; F Adami; A Cipriani; R Zambello; G Semenzato
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

9.  Interleukin-15 protects from lethal apoptosis in vivo.

Authors:  S Bulfone-Paus; D Ungureanu; T Pohl; G Lindner; R Paus; R Rückert; H Krause; U Kunzendorf
Journal:  Nat Med       Date:  1997-10       Impact factor: 53.440

10.  Interleukin-15 induces adhesion receptor redistribution in T lymphocytes.

Authors:  M Nieto; M A del Pozo; F Sánchez-Madrid
Journal:  Eur J Immunol       Date:  1996-06       Impact factor: 5.532

View more
  7 in total

Review 1.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

2.  B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients.

Authors:  Raphael Schneider; Alma Nazlie Mohebiany; Igal Ifergan; Diane Beauseigle; Pierre Duquette; Alexandre Prat; Nathalie Arbour
Journal:  J Immunol       Date:  2011-09-12       Impact factor: 5.422

Review 3.  IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction.

Authors:  Bana Jabri; Valérie Abadie
Journal:  Nat Rev Immunol       Date:  2015-11-16       Impact factor: 53.106

Review 4.  IL-15: a central regulator of celiac disease immunopathology.

Authors:  Valérie Abadie; Bana Jabri
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

5.  Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.

Authors:  Jeppe Romme Christensen; Lars Börnsen; Dan Hesse; Martin Krakauer; Per Soelberg Sørensen; Helle Bach Søndergaard; Finn Sellebjerg
Journal:  J Neuroinflammation       Date:  2012-09-14       Impact factor: 8.322

6.  Interleukin-15 enhances proinflammatory T-cell responses in patients with MS and EAE.

Authors:  Cyril Laurent; Gabrielle Deblois; Marie-Laure Clénet; Ana Carmena Moratalla; Negar Farzam-Kia; Marc Girard; Pierre Duquette; Alexandre Prat; Catherine Larochelle; Nathalie Arbour
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-12-15

7.  Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer.

Authors:  Thomas A Waldmann; Milos D Miljkovic; Kevin C Conlon
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.